## SENTARA COMMUNITY PLAN (MEDICAID)

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete</u>, correct, or legible, authorization may be delayed.

Drug Requested (Choose one from below	w):		
□ Albenza® (albendazole)	□ Emverm® (mebendazole)		
MEMBER & PRESCRIBER INFO	RMATION: Authorization may be delayed if incomplete.		
Member Name:			
Member Sentara #:	Date of Birth:		
Prescriber Name:			
Prescriber Signature:			
Office Contact Name:			
Phone Number:	Fax Number:		
DEA OR NPI #:			
DRUG INFORMATION: Authorizati	ion may be delayed if incomplete.		
Drug Form/Strength:			
	Length of Therapy:		
Diagnosis:	ICD Code, if applicable:		
Weight:	Date:		
• {Trial of pyrantel pamoate <u>required</u> for <u>I</u>	Pinworm and Hookworm infections.		
• Listed below are the Center for Disease Hookworm:	e Control recommendations for treatment of Pinworm and		

CDC Recommendations for <u>Pinworm</u> Treatment	Dosage for Adults and Children
Pyrantel pamoate (preferred)	• 11mg/kg base PO once; repeat in 2 weeks
Mebendazole (non-preferred)	• 100mg PO once; repeat in 2 weeks
Albendazole (preferred)	<ul> <li>For children ≥20kg: 400mg PO once; repeat in 2 weeks</li> <li>For children &lt;20kg: 200mg PO once; repeat in 2 weeks</li> </ul>

CDC Recommendations for <u>Hookworm</u> Treatment	Dosage for Adults and Children
Pyrantel pamoate (preferred)	• 11mg/kg (up to a maximum of 1gm) PO daily for 3 days
Mebendazole (non-preferred)	100mg PO BID for 3 days or 500mg orally once
Albendazole (preferred)	• 400mg PO once

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

□ For <u>Pinworm infection</u>: Patient has tried and failed <u>at least 2 doses</u> of a pyrantel pamoate product - initial dose followed by second dose 2 weeks later. Paid pharmacy claim for a pyrantel pamoate product <u>MUST</u> be noted in patient's pharmacy profile.

## **OR**

□ For <u>Hookworm infection</u>: Patient has tried and failed <u>at least 3 consecutive daily doses</u> of a pyrantel pamoate product. Paid pharmacy claim for a pyrantel pamoate product <u>MUST</u> be noted in patient's pharmacy profile.

## **AND**

If requesting Emverm or brand Albenza, member must meet <b>ONE</b> of the following:
☐ Member has trial and failure or an inadequate response to albendazole
☐ Member has an intolerance, hypersensitivity or contraindication to albendazole

\*\*Use of samples to initiate therapy does not meet step edit/preauthorization criteria.\*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\*